Machine perfusion in transplantation (Sponsor: Novartis Pharma GmbH, Nürnberg)
Therapieforum Transplant · 01.06.2018 · 06 (01) · 4-13
DOI: 10.1055/a-0667-7056 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapieforum Transplant, erschienen am 01.06.2018.
Abstract (Originalsprache)
The preservation of donor organs through machine perfusion (MP) creates new opportunities in transplantation medicine for the benefit of patients. In view of the organ shortage and the increasing number of marginal organs, there is a need to establish MP in Germany in order to improve organ utilization and therapeutic outcomes. In kidney transplantation, the use of MP can significantly improve 1-year survival. MP also offers advantages in liver, heart, and lung transplantation. As recommended by the Organ Donation Committee (KfO, Kommission für Organspende) of the German Transplantation Society (DTG, Deutsche Transplantationsgesellschaft) as well as the Permanent Committee on Organ Transplantation (StäKO, Ständige Kommission Organtransplantation), its use should be initially adopted in standard care in the form of hypothermic machine perfusion in kidney transplantation and then be further extended.
Zitieren
APA
(2018). Machine perfusion in transplantation (Sponsor: Novartis Pharma GmbH, Nürnberg). Therapieforum Transplant, 06(01), 4-13. https://doi.org/10.1055/a-0667-7056
Vancouver
Machine perfusion in transplantation (Sponsor: Novartis Pharma GmbH, Nürnberg). Therapieforum Transplant. 2018;06(01):4-13. doi:10.1055/a-0667-7056
BibTeX
@article{euvimed2018,
title = {Machine perfusion in transplantation (Sponsor: Novartis Pharma GmbH, Nürnberg)},
journal = {Therapieforum Transplant},
year = {2018},
volume = {06},
number = {01},
pages = {4--13},
doi = {10.1055/a-0667-7056}
}
EUVIMED